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Abstract Current ClASsification criteria for Psoriatic
ARthritis classification criteria for psoriatic arthritis (PsA)
provide a preliminary definition of inflammatory articular dis-
ease. This study aimed to further characterize PsA peripheral
arthritis using purely data-driven approaches for the affected
joint distribution pattern. PsA patients from the Swiss Clinical
Quality Management in Rheumatic Diseases (SCQM) data-
base were clustered according to similarities in 66 swollen and
in 68 tender joints. Clusters were compared in terms of other
disease characteristics and studied for coincidence with tradi-
tional PsA subtypes, stability over time and treatment re-
sponse upon first tumour necrosis factor alpha (TNF-α) ther-
apy. Clustering of 957 patients resulted in an oligoarticular, a
polyarticular hand dominated, a polyarticular foot dominated
and a fourth cluster which was characterized by polyarticular
involvement of the hands and feet. Of the traditional PsA
subtypes, only a non-PsA-specific oligoarticular joint
involvement pattern was retrieved by clustering. When com-
paring clusters in other disease manifestations, onlyminor and
clinically probably irrelevant differences occurred. Over time,
clusters were more robust than traditional PsA subtypes.
Patients in different joint clusters had similar response rates
upon first anti-TNF-α therapy, and minimal disease activity
was achieved in 56% of 285 patients, irrespective of cluster
membership. Hypothesis-free approaches to group PsA pa-
tients yield clusters with improved consistency, but without
clinically important differences. Taken together, the current
peripheral arthritis definition by GRAPPA without further
specification into subtypes is strongly supported by the data.
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Introduction
Psoriatic arthritis (PsA) is typically an autoantibody negative,
chronic inflammatory disease of synovial joints, peritendinous
tissues and entheses, usually in association with psoriatic skin
or nail disease. Both psoriatic skin and joint disease have a
strong genetic background [1], which appear to be different in
some important gene loci of immune response regulation [2].
Furthermore, another recent study indicated some genetic dif-
ferences in relation to the PsA phenotype [3], but the com-
plexity of PsAmanifestations is not fully explained by current
genetic data. Tumour necrosis factor alpha (TNF-α) and dif-
ferent cytokines of the IL-23/IL-17 axis currently are
established treatment targets in PsA [4].
Moll and Wright were the first to describe a set of more or
less typical traditional PsA subtypes [5], which were later
defined in more detail for research purposes [6]. Distal
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Hypothesis-free analyses from a large psoriatic arthritis cohort
support merger to consolidated peripheral arthritis definition
without subtyping
interphalangeal (DIP) peripheral joint involvement alone, of-
ten in conjunction with psoriatic nail disease [7], is considered
to be specific enough to allow for PsA diagnosis [8]. In con-
trast, other PsA subtypes share dominant features with other
rheumatic entities, e.g. axial disease with other types of
spondyloarthritis (SpA), or symmetric polyarticular disease
with rheumatoid arthritis (RA). Symmetry in joint involve-
ment is a function of its number [9]. The more joints involved
are in PsA, the more resemble PsA disease manifestations RA.
Furthermore, at an individual time-point, a single patient may
satisfy several different subtypes and a patient may switch
from one subtype to another over time [10].
Following a currently discussed anatomy-based hypothe-
sis, unknown site-specific factors may linkDIPmanifestations
to inflamed anchorage tendon fibres between the psoriatic
nails, the finger extensor tendons and the periosteum
[11–13]. In contrast, large joints, metacarpophalangeal
(MCP) joints or proximal interphalangeal (PIP) joints, which
are typically involved in oligoarticular or symmetric
polyarticular PsA, would lack a direct connection to the nails,
thereby suggesting that other pathologies may be dominant in
these subtypes. In another current disease concept, arthritis
may, in analogy to the Koebner phenomenon of psoriatic skin,
be triggered by repeated microtrauma in genetically or other-
wise susceptible individuals, thereby activating locally accu-
mulated immune cells in an autoinflammatory fashion [14].
Assuming highly individual movement behaviours, a huge
heterogeneity in joint involvement patterns would be the con-
sequence of this disease model.
While the debate about the existence and relevance of PsA
subtypes for the clinics is ongoing [10, 15], details of periph-
eral joint involvement were not included in the current broad
preliminary ClASsification criteria for Psoriatic ARthritis
(CASPAR) definition of inflammatory articular disease, but
postponed to the research agenda [16]. In the present study,
we utilized a fully data-driven approach in order to obtain any
characteristic peripheral joint involvement pattern. We aimed
specifically to reproduce the traditional subtypes as far as de-
fined on a peripheral joint basis. In their absence, we would
consider equivalence of peripheral arthritis in any location for
disease definition. Consequently, the current preliminary def-
inition of peripheral joint PsA without specification in its lo-
calization would gain additional support [5, 16].
Methods
Patients and setting
This study was nested in the Swiss Clinical Quality
Management in Rheumatic Diseases (SCQM) program in
rheumatic diseases. All 957 patients with a definite diagnosis
of PsA according to the CASPAR classification criteria were
included into analysis [16]. This study was performed in com-
pliance with the Helsinki Declaration from 1964. Patients pro-
vided written informed consent prior to inclusion. Ethical ap-
proval for patient enrolment into the SCQM program and
related studies was obtained from the Swiss Academy of
Medical Sciences review board. Patient registration in
SCQM is restricted to board-certified rheumatologists. Data
for this study were collected from 1997 until May 2015. More
than 65% of the rheumatologists, who contributed data on
PsA patients, were from private practices.
Disease variables
Peripheral joint manifestation data consisted of ‘involved’/
‘not involved’ for both swelling and tenderness in each joint
of the 66/68 joint status [17]. Descriptive data and the data for
the cluster analyses were obtained at the same time-point un-
less otherwise stated. Traditional PsA joint involvement
groups were defined according to a later specification of the
Moll and Wright criteria as ‘oligoarthritis type’ in the case of
less than five affected joints, the ‘DIP joint predominance
type’ in the case of >50% of the total joint count being DIP
joints, and a ‘symmetric type’ was defined when >50% of
joints in non-oligoarticular and non-DIP type patients were
involved in a symmetrical manner [6].
Dichotomous stand-alone variables, human leukocyte anti-
gen (HLA)-B27 status, CASPAR classification items (current
psoriasis, personal or family history of psoriasis, history of
dactylitis, enthesitis, axial disease, nail manifestations and
rheumatoid factor status) were collected from any visits since
inclusion. Disease-defining radiographic data were assimilat-
ed from the local evaluations of the treating rheumatologists.
Time-dependent dichotomous data included current treatment
with non-steroidal anti-rheumatic drugs (NSAIDs), corticoste-
roids, synthetic long-acting anti-rheumatic drugs (DMARD)
and anti-TNF-α agents. Current psoriatic skin activity was
repeatedly assessed on a 7-point Likert scale, and had to be
documented on at least one occasion as being mild or more
severe, in order to satisfy the current skin psoriasis criterion in
the CASPAR classification criteria [16]. Patient and physician
global assessment of disease activity and patient pain were
collected on 10-point Likert scales. Time-dependent continu-
ous parameters included erythrocyte sedimentation rate
(ESR), C-reactive protein (CRP), the disease activity score
in 28 joints (DAS-28) [18], the Stanford health assessment
questionnaire of disability index (HAQ-DI) [19], the Short-
Form Health Survey (SF-36) and the dermatology life quality
index (DLQI) [20].
Minimal disease activity
We compared the clusters for the proportion of patients
achieving a status of minimal disease activity (MDA) at
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12months (±3 months) after start of the first documented anti-
TNF-α therapy [21]. If multiple visits were available in the
time-window, the visit closest to 12 months was chosen. If no
visit was available within this time window, the last visit be-
tween 2 and 9 months after the start of ongoing anti-TNF-α
treatment was utilized. Absent or almost absent current psori-
asis skin activity on the 7-point-scale substituted for the miss-
ing Psoriasis Area and Severity Index (PASI) [22]. In order to
compensate for missing repeated assessment of enthesitis
scores, which were according to OMERACT 8 only defined
as not mandatory domains [23], we approximated ‘possibly in
MDA’ on the basis of four fulfilled out of the six remaining
domains. ‘Definitive MDA’ was defined using fulfilment of
five out of the six repeatedly completed domains. In a sensi-
tivity analysis, we calculated MDA in five out of seven do-
mains for patients with absent enthesitis at any completed
visit. Furthermore, an additional sensitivity analysis, using
an enlarged response population by including 126 subjects
with probable PsA according to the medical diagnosis of the
treating rheumatologist, was performed.
Statistics
Swollen joint data was chosen as the primary variable to be
analysed in a data-driven strategy of hierarchical clustering
given the more objective nature of this variable compared
with the tender joint data. The Manhattan distance, simply
counting the number of joints that are differently involved
or not involved in two patients, was used as metric and
complete linkage clustering method, due to its property
of deriving compact clusters. We compared this method
with other established clustering approaches, but found
none of them to be more suitable. In secondary analyses,
patients were analysed with the same statistical procedures
based on their tender joint data.
Patient transitions between joint involvement clusters or
traditional PsA subtypes were predicted using k-nearest
neighbour classification (k = 10, no constraints) trained on
the data as assigned to the respective clusters at inclusion
and predicted 1 year later.
The effect of the cluster membership on MDA after start of
a first anti-TNF-α therapy was assessed using logistic regres-
sion. We assessed the changes in single disease activity out-
come measures using an analysis of covariance with robust
regression for non-normally distributed scale-based single dis-
ease activity outcome measures in a completers-only ap-
proach. Improved involvement on a single joint level was
evaluated using Fisher’s exact test. Multiple testing correction
was performed either using the methods of Bonferroni or
Benjamini-Hochberg [24] when indicated. A 5% significance
level was defined. All analyses were performed in the statis-
tical software ‘R’.
Results
Patient clustering on peripheral swollen joints
The hierarchical clustering was optimized to yield a fea-
sible number of groups, which resulted in four clusters.
A detailed description of the clinical status at inclusion
of all 957 patients with definite PsA [16] grouped into
these four clusters is provided in Table 1. The dendro-
gram illustrates that the largest cluster of 748 patients
separated first from the other patients (Fig. 1). Swollen
joints in this cluster could be at any location, but with a
median of one swollen joint (IQR 0–4), the numbers
were characteristically low. This ‘oligoarticular’ cluster
also included patients with currently absent or inactive
peripheral arthritis. Next, a cluster of patients with pre-
dominant feet involvement separated (n = 70). The final
split occurred between the patients with hand-dominant
arthritis (n = 123) and a so-called polyarticular cluster
composed of patients with many swollen joints at their
hands and feet (n = 16). By cluster definition on tender
joint data, 71% of all subjects were assigned to the same
cluster as defined by swollen joints. In a sensitivity anal-
ysis, repeating the same statistical operations on swollen
and tender joint data in the anti-TNF-α-naïve patients at
inclusion (n = 464), clusters with the same four qualities
were retrieved (data not shown).
Comparison of clusters for other disease characteristics
When comparing obtained clusters for other clinical dis-
ease features, patients were significantly older in the
polyarticular and hand-dominated clusters. Skin psoriasis
was currently less active, and current DIP predominant
joint involvement as well as dactylitis in the patients’ past
history were significantly less frequent in the oligoarticular
cluster compared with the other clusters. In contrast, no
differences were detected among the clusters for disease-
defining psoriatic nail pathologies, spinal involvement,
enthesitis or the presence of characteristic radiological fea-
tures of PsA. The full set of comparisons between the four
swollen joint clusters is reported in Table 1.
As 29% of patients were allocated to another cluster
on the basis of tender joint data compared with swollen
joint data, tender joint clusters and their comparisons dif-
fered in some parameters from those performed on swol-
len joint clusters, e.g. for enthesitis prevalence. These
data are reported in Supplementary Table 1. All the sub-
sequent analyses were performed for both, swollen and
tender joint clusters. For simplicity, as both clusters led
to comparable results, we will only present the swollen
joint cluster data.
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Comparing mathematical clusters with predefined
peripheral joint PsA subtypes
Seventy percent of patients in the oligoarticular cluster formal-
ly fulfilled the traditional oligoarticular PsA subtype definition
[6], but the other, more PsA characteristic traditional subtypes
were not retrieved by clustering the swollen joints. DIP joints
were less frequently involved than the MCP or PIP joints in
any swollen joint cluster (Fig. 2). DIP predominance was only
retrieved in secondary tender joint analyses among patients
with hand-dominated joint involvement (Supplementary
Fig. 1). Also, symmetric tender joint features were overrepre-
sented in the hand-dominated and polyarticular clusters.
Stability of clusters and traditional PsA subtypes over time
Follow-up data of this cohort was obtained from a median of
four visits (IQR 3–6) collected over a median of 3.1 years
(IQR 1.5–5.3). We investigated whether patients remained in
their initial allocated clusters at the 1-year follow-up visit.
There was unidirectional migration towards the oligoarticular
cluster in 13% of patients (Fig. 3a). In contrast, bidirectional
Table 1 Descriptive statistics of
clusters based on swollen joint
data for patients with CASPAR-
positive definite PsA at inclusion
Oligo
N = 748
Poly
N = 16
Hands
N = 123
Feet
N = 70
P value
Female 46% 31% 46% 39% 0.46
Age 48 (40–57) 55 (50–58) 50 (44–60) 45 (41–54) 0.004
Disease duration 6 (2–13) 4 (2–8) 6 (2–11) 5 (3–8) 1
Arthritis ever 92% 100% 100% 100% 0.0005
Enthesitis ever 63% 70% 67% 60% 0.79
Spinal disease ever 43% 38% 41% 42% 0.95
Current skin psoriasis 83% 94% 91% 97% 0.001
Psoriasis patient history 97% 100% 98% 97% 0.85
Psoriasis family history 35% 13% 38% 51% 0.05
Nail psoriasis ever 29% 17% 32% 33% 0.87
Negative RF ever 97% 90% 99% 100% 0.28
Dactylitis ever 66% 94% 81% 91% 0.0005
Radiographic criterion 31% 33% 39% 33% 0.63
Oligoarticular 70% 0% 2% 6% 0.0005
DIP-predominant 3% 0% 3% 0% 0.55
Any DIP involvement 11% 38% 31% 40% 0.0005
Symmetric polyarticular 15% 100% 57% 57% 0.0005
Inflammatory back pain ever 34% 50% 33% 31% 1.00
HLA-B27-positive 10% 6% 7% 9% 0.45
Anti-TNF-α 52% 38% 54% 50% 0.09
DMARD 63% 81% 65% 71% 0.25
Corticosteroids 9% 19% 20% 13% 0.0085
NSAID 52% 88% 63% 80% 0.0005
SJC66 1 (0–4) 24 (17–34) 10 (4–12) 13 (2–17) <0.0001
SJC28 1 (0–2) 20 (10–22) 7 (0–10) 4 (0–7) <0.0001
CRP [mg/l] 6 (2–9) 11 (8–29) 8 (4–17) 8 (5–16) 0.0018
ESR [mm/h] 10 (5–20) 29 (15–59) 14 (6–25) 16 (11–36) 0.0001
Physician global 3 (2–5) 7 (6–8) 5 (3–7) 5 (4–7) <0.0001
Patient global 4 (2–7) 3 (3–7) 6 (3–7) 7 (4–8) <0.0001
Patient pain 5 (2–7) 3 (3–9) 6 (3–8) 6 (4–8) <0.0001
Data are from the visit used for cluster analysis unless otherwise stated. P values are from Fisher’s exact test for
nominal variables or a Wilcoxon rank-sum test for continuous/ordinal variables. No multiple testing correction
was performed. For continuous variables, medians and interquartile ranges (in parentheses) and, for nominal
variables, proportions (in %) are reported
CRP C-reactive protein, DIP distal interphalangeal, DMARD synthetic disease-modifying anti-rheumatic drugs,
ESR erythrocyte sedimentation rate, NSAID non-steroidal anti-inflammatory drugs, RF rheumatoid factor, SJC
swollen joint count on the basis of 28/66 joints
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migration was observed in 26% of cases between the tradi-
tional PsA subtypes (Fig. 3b). These observations were con-
firmed in clusters as well as traditional subtypes when based
on tender joint data, and in all subgroup analyses limited to
anti-TNF-α-naïve patients (n = 464), to only patients with
axial involvement (n = 397) and to only patients with
dactylitis (n = 664, data not shown).
Response to anti-TNF-α therapy in joint clusters
Clinical response to treatment was examined in 285 patients
with follow-up data at 12 ± 3 months after initiation of their
first documented anti-TNF-α therapy. This population was
representative of the entire study population with regards to
observation time, visit counts and all reported disease param-
eters. One hundred seventeen (56%) patients were possibly in
a state of MDA according to the 4/6 rule, and 78 (38%) pa-
tients were definitely in a state of MDA according to the 5/6
rule, at the time of follow-up. The proportion of patients dem-
onstrating possible or definite MDA among the clusters
ranged from 35 to 58%. No significant effect of the joint
clusters on achieving MDAwas found by logistic regression
analysis irrespective of the rule of MDA definition. In the
sensitivity analysis only including enthesitis-negative patients,
74 patients (41%) achieved MDAwith similar proportions in
all the clusters (39–50%). Cluster allocations had no signifi-
cant effect on the evolution of any of the tested single-
response items upon first anti-TNF-α therapy in a robust
ANCOVA after multiple testing correction (Table 2). The
same was true for clusters on tender joint basis (data not
shown). As some swollen joint clusters in CASPAR-positive
patients were too small for a definitive statement, the
Fig. 1 Unpruned dendrogram of
hierarchical clustering on the
swollen joint manifestations in
patients with definite PsA [16].
The first split occurs between the
large oligoarticular cluster (red)
and the rest. Then, at a distance of
about 350, the feet-dominated
cluster (blue) is separated from
the rest, followed by the split into
the polyarticular (green) and
hand-dominated clusters (purple)
at a distance of about 170 (colour
figure online)
Fig. 2 Characterization of the four clusters with respect to joint involvement patterns in the swollen data.Colour strength indicates proportion of patients
with respective involved joint
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population was enlarged to a total of 411 patients, resulting in
20 subjects in the smallest cluster, by including formally
CASPAR-negative patients. Negative classification was most
frequently caused by missing data. All these individuals had
PsA according to the medical diagnosis of the treating rheu-
matologist. Still, cluster membership on swollen joints
remained an insignificant parameter for the results obtained
in these secondary anti-TNF-α response analyses (data not
shown). Finally, we looked at the responsiveness to TNF
blockade for single joints in the original CASPAR-positive
cohort. A median of 64% of swollen and 47% of tender joints
improved upon anti-TNF-α therapy with only some
quantitative difference in dependence of their localization
(Fig. 4). Response rates upon anti-TNF-α therapy in DIP
joints were similar to other PsA joint manifestations.
Discussion
In this study, we aimed to further detail the current arthritis
definition without subtyping given in the CASPAR classifica-
tion criteria by stringent application of data-driven statistical
methods in one of the few currently available large PsA co-
horts with a full status including 66/68 joints [8, 16, 25]. This
Table 2 Response to treatment
with anti-TNF-α after 1 year in
the four clusters
Oligo
N = 207
Poly
N = 8
Hands
N = 41
Feet
N = 29
SJC 66 −1 (−3–0) −10 ([−16]–[−2]) −7 ([−9]–[−1]) −11 ([−17]–[−6])
TJC 68 −1 (−4–0) −6 ([−8]–[−3]) −5 ([−12]–[−1]) −11 ([−19]–[−5])
Current skin psoriasis −1 (−2–0) 0 (0–0) −1 (−2–0) −1 (−2–0)
Patient global −2 (−5–0) −1 (−1–0) −2 (−3–1) −4 ([−7]–[−2])
Patient pain −2 (−4–0) −1 ([−2]–[−1]) −2 (−3–0) −2 ([−6]–[−1])
HAQ-DI 0 (−1–0) 0 (0–0) 0 (−1–0) 0 (−1–0)
DLQI −1 (−6–0) No data −1 ([−5]–[−1]) 0 (0–0)
SF-36 PCS 5 (0–12) 5 (0–9) 7 (−1–9) 10 (1–13)
SF-36 MCS 1 (−2–5) −2 (−9–4) 5 (0–9) 8 (0–11)
Physician global −2 (−3–0) −3 ([−4]–[−2]) −3 ([−5]–[−1]) −3 ([−6]–[−2])
CRP [mg/l] 0 (−6–0) −2 (−15–0) 0 (−8–0) −4 (−12–0)
ESR [mm/h] −4 (−14–0) −6 ([−16]–[−2]) −2 (−6–2) −8 ([−31]–[−2])
DAS28 (CRP) −1 (−2–0) −1 (−2–0) −1 (−2–0) −2 (−2–0)
Median decrease and interquartile ranges (in parentheses) of different response parameters from start of anti-TNF-
α treatment to 1 year later in the four clusters. None of the investigated response criteria showed significant
change in a robust ANCOVA after multiple testing correction. SJC swollen joint count on the basis of 66 joints,
TJC tender joint count on the basis of 68 joints, HAQ-DI health assessment questionnaire disability index, DLQI
Dermatology Life Quality Index, SF-36 PCS/MCS short-form health survey physical/mental component score
CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 (CRP) disease activity score based on 28
joints and CRP
Fig. 3 Transition of patients between clusters (a) and traditional PsA
subtypes (b) going from inclusion to follow-up. Arrows indicate
direction of transition as well as number. Circles indicate the size of the
respective clusters at inclusion. Absolute numbers at the respective start
points are given in parentheses. The ‘Hands & Feet’ circle corresponds to
the ‘polyarticular cluster’ from the text
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study confirmed the reported large variability of involved
joints in their number and location. We found moderate to
good agreement between swollen joint and tender joint cluster
definitions, but were unable to satisfactorily reproduce the
traditional PsA subtypes. We found improved robustness of
the clusters over time as compared to previous subtype defi-
nitions, but clusters had no other clinically relevant differences
than their peripheral joint status. Furthermore, cluster stability
over time was still insufficient for a rational basis of true sub-
entity definition in PsA.
A precise definition of arthritis in PsA purely with regards
to the presence or absence of tenderness and swelling has its
limitations [17, 26]. Available alternatives with a higher level
of precision would be X-ray studies, which do not cover early
disease phases. Evaluation studies on more precise imaging
modalities necessary to detect early pathologies and to clearly
distinguish arthritis from joint-adjacent enthesitis are still un-
der investigation [27]. Moreover, more sophisticated methods
such as high-resolution MRI or ultrasound would hardly be
feasible due to the many locations, the variability and the large
number of individuals to be studied without prior preparation
using rather crude clinical assessments.
Despite the restriction of clinical assessors to board-
certified rheumatologists as required by CASPAR [16], with
at least 1 year of post-graduate Rheumatology education in a
large teaching or university hospital, the setting of many pa-
tients coming from outside specialized PsA research centres
might raise concerns about the validity of the data. For in-
stance, 70% cumulative dactylitis prevalence over time is
higher than expected, which may indicate some uncertainties
in the assessment or overestimation of this important disease
symptom in routine daily practice. On the other hand, being
closer to the ‘real world’may also be considered as a strength,
as long as central data validation by review of each single item
of the CASPAR classification criteria compensated for major
issues [28]. The association of psoriatic nail and DIP involve-
ment could not be addressed with only general data on nail
pathologies [7, 29]. Restriction of response data to the PsA
core set domains according to OMERACT 8 [23] in the
SCQM registry without repeated enthesitis scores and skin
assessment on only ordinal data level caused calculable im-
precisions for MDA calculation.
Patients could be included into the SCQM registry at any
time after diagnosis. The patients in this study had a tendency
towards shorter disease duration and lower median joint
counts than in the few other large cohorts with available re-
ports on the 66/68 joint status [10, 16, 25]. TNF-α inhibition
was usually started in monotherapy, or as add-on to metho-
trexate (MTX), which was the DMARD of choice in 69% of
cases. Limited patient numbers or lower baseline disease ac-
tivity prevented other response analyses, but we assume that
MTX had, if at all, only a limited effect on the clinical presen-
tation and study outcome [30].
We could exclude significant effects on the peripheral ar-
thritis clusters by anti-TNF-α in treatment-specific subgroup
analyses.
There has been some controversy about whether more de-
tailed subtypes in PsA should be maintained or whether division
should be restricted to only two subtypes of peripheral and axial
disease [10]. Subtype definitions should be as distinct as diagno-
ses in general; they should be mutually exclusive and, ideally,
collectively exhaustive.When applying these requirements to the
traditional PsA subtypes, oligoarthritis cannot, strictly speaking,
be considered PsA-specific. Furthermore, many cases of
polyarticular joint involvement in the present study resembled
the 1987 ACR RA criterion of symmetry, while others did not,
thereby dissecting another traditional PsA subtype by data anal-
ysis. In addition, patients with the most characteristic DIP pre-
dominance, or with at least someDIP involvement for definition,
Fig. 4 Counts of joint swelling and tenderness before and after anti-
TNF-α treatment. Joint swelling (blue) or tenderness (red) before start
of anti-TNF-α treatment (lighter colours) and frequency of joint
involvement at follow-up visit (darker). Stars indicate level of
significance from a per location Fisher’s exact test. False discovery rate
was controlled using Benjamini-Hochberg correction (colour figure
online)
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were scattered among all the mathematically defined clusters,
and the majority of these cases fell into the same mathematically
defined hand cluster as the traditional polyarticular symmetric
subtype. Taking all these comparative observations in clusters
and in traditional subtypes together, with bi-directional migration
in the latter, data-driven approaches did clearly not support the
traditional peripheral joint-based PsA subtypes.
With the exception of dactylitis frequency, which is by
definition not unrelated to peripheral joint involvement, we
found no other significant differences between the obtained
clusters. More importantly, from a clinical point of view, we
observed no significant differences in achieving MDA upon
anti-TNF-α therapy, the current first choice of target-specific
treatment in PsA [31]. Often, harder joint capsules upon pal-
pation even in actively inflamed DIP joints in PsA may give
rise to suggest different pathologies in these than in others
such as MCP joints. However, similar improvement rates up-
on anti-TNF-α therapy in the different localizations may indi-
rectly support appropriate DIP arthritis assessment being truly
inflammatory. Furthermore, obtained improvement rates were
clearly superior to those observed in osteoarthritis [32, 33].
Thus far, cluster membership of peripheral joints would
currently have no clinical implications on the treatment
choice. Without a principle reservation of possible differential
therapeutic effects on different joints for future treatment mo-
dalities, it appears unnecessary to develop subtype-specific
treatment response criteria on the basis of peripheral joint
involvement. This statement does not exclude the usefulness
of subtyping of PsA patients according to more general do-
mains such as axial disease or enthesitis. Authors of a recent
abstract came to a similar conclusion [34].
In summary, we found relevant conceptual issues regarding
traditional PsA subtypes, but were not able to offer better data-
driven alternative-defining subtypes on the basis of peripheral
joint involvement. Ongoing research may lead in the future to
meaningful subtype systematics on another basis, e.g. by mor-
phology or genetics. Thus far, the present data support the
current designation of peripheral arthritis without further
specification.
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